Ziresovir

Ziresovir
Clinical data
Trade namesZiresovir
Legal status
Legal status
Identifiers
IUPAC name
  • N-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-2H-1λ6,4-benzothiazepin-4-yl)-6-methylquinazolin-4-amine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC22H25N5O3S
Molar mass439.5 g·mol−1
3D model (JSmol)
SMILES
  • CC1=CC2=C(C=C1)N=C(N=C2NCC3(COC3)N)N4CCS(=O)(=O)C5=CC=CC=C5C4
InChI
  • InChI=1S/C22H25N5O3S/c1-15-6-7-18-17(10-15)20(24-12-22(23)13-30-14-22)26-21(25-18)27-8-9-31(28,29)19-5-3-2-4-16(19)11-27/h2-7,10H,8-9,11-14,23H2,1H3,(H,24,25,26)
  • Key:GAAICKUTDBZCMT-UHFFFAOYSA-N

Ziresovir (RO-0529, AK0529) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown good results in Phase II clinical trials.[1][2]

See also

References

  1. ↑ Zheng X, Gao L, Wang L, Liang C, Wang B, Liu Y, et al. (July 2019). "Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor". Journal of Medicinal Chemistry. 62 (13): 6003–6014. doi:10.1021/acs.jmedchem.9b00654. PMID 31194544.
  2. ↑ Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC (July 2019). "Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference". Antiviral Research. 167: 45–67. doi:10.1016/j.antiviral.2019.04.006. PMC 7132446. PMID 30974127.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.